Home・Lista de Ações・ENANTA PHARMACEUTICALS INC

ENANTA PHARMACEUTICALS INC

Fechado

SetorSaúde

13.25 3.27

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

12.53

Máximo

13.62

Indicadores-chave
By Trading Economics
Rendimento	-1.2M -13M
Vendas	-1.5M 17M
EPS	-0.45
Margem de lucro	-76.292
Funcionários	120
EBITDA	-958K -8.6M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+54.44% upside

Dividendos
By Acuity
Próximos Ganhos	7 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-52M 370M
Abertura anterior	9.98
Fecho anterior	13.25

Sentimento de Notícias

By Acuity

31%

69%

97 / 340 Ranking em Healthcare

ENANTA PHARMACEUTICALS INC Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de ago. de 2026, 19:23 UTC

Enanta Pharmaceuticals Inc shares are rising amid a broader market rally, supported by gains in major technology stocks and renewed investor confidence.

31 de jul. de 2026, 20:06 UTC

Enanta Pharmaceuticals Inc's shares are lower today, continuing a downward trend amid rising U.S. Treasury yields and crude oil prices. No specific news was identified.

30 de jul. de 2026, 19:45 UTC

Enanta Pharmaceuticals Inc. is advancing, supported by broader market gains. Earlier in the session, shares pulled back from a session high.

29 de jul. de 2026, 18:26 UTC

Enanta Pharmaceuticals Inc is declining in Wednesday's session, marking the seventh consecutive day of lower prices. No specific news has been identified to explain the movement.

28 de jul. de 2026, 20:06 UTC

Enanta Pharmaceuticals Inc is declining, marking five consecutive sessions lower. The stock peaked earlier but has since pulled back amid broader market pressures.

27 de jul. de 2026, 18:36 UTC

Enanta Pharmaceuticals Inc is higher today, building on Friday's momentum amid broader market dynamics following a decline in oil prices.

24 de jul. de 2026, 20:06 UTC

Enanta Pharmaceuticals Inc. shares are lower today, reversing from a recent trend of higher daily closes since Thursday's close.

21 de jul. de 2026, 19:31 UTC

Enanta Pharmaceuticals is rising during Tuesday's session, reflecting broader market strength and positive sentiment from recent earnings reports by General Motors and Novartis.

20 de jul. de 2026, 19:46 UTC

Enanta Pharmaceuticals Inc shares are lower today, continuing a decline since Friday's close. The stock has shown significant volatility during the session.

Comparação entre Pares

Variação de preço

ENANTA PHARMACEUTICALS INC Previsão

Preço-alvo

By TipRanks

54.44% parte superior

Previsão para 12 meses

Média 20 USD 54.44%

Máximo 20 USD

Mínimo 20 USD

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para ENANTA PHARMACEUTICALS INC - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

1 ratings

Comprar

Manter

Vender

Com base em 1 analistas que deram avaliações de ações para ENANTA PHARMACEUTICALS INC - Dist nos últimos 3 meses.

Sentimento

By Acuity

97 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.